Citation Information :
Ozkarafakili MA, Melekoğlu A, Altinbilek E. Clinical Evaluation of Chronic Obstructive Pulmonary Disease Patients Hospitalized with COVID-19 Pneumonia. Indian J Respir Care 2023; 12 (1):23-29.
Background: Coronavirus disease 2019 (COVID-19) has been a challenging viral respiratory tract infection since 2019 and may contribute to higher mortality in patients with chronic obstructive pulmonary disease (COPD).
Methods: We analyzed the clinical data of 98 patients hospitalized with a diagnosis of COVID-19 and who had a previous diagnosis of COPD. They are grouped regarding GOLD ABCD stages, reported as follows whether in pandemic wards or intensive care units (ICU). The clinical outcomes were noted as a live hospital discharge or inhospital mortality.
Results: A total of 76 patients (77.6%) were in the pandemic wards, 22 (22.4%) were in the ICU. Around 81 (82.7%) patients survived, 17 (17.3%) were deceased. We grouped them as GOLD A and GOLD B and GLOD C, and GOLD D. Procalcitonin (PCT) level was higher and arterial oxygen partial pressure (PaO2 in mm Hg) to fractional inspired oxygen (PaO2/FiO2) level was lower in the group of GOLD C and GOLD D than in GOLD A and GOLD B (p < 0.005). There was no statistically significant difference in inhospital mortality between these two groups (p = 0.098). While in the univariate model, hemoglobin (Hgb), urea, troponin, PCT, PaO2/FiO2, saturation%, and respiratory rate was observed to be significantly different; in the multivariate model, only a significant independent (p < 0.05) effect of PaO2/FiO2 were observed in distinguishing patients who survived or deceased.
Conclusion: Global Initiative for Chronic Obstructive Lung Disease (GOLD) ABCD groups are staging COPD patients in favor of predicting hospitalization and mortality. However, when COPD patients are hospitalized with COVID-19 pneumonia, different clinical factors and indices should be considered due to the heterogeneity and complexity of COPD.
Transmission of SARS-CoV-2: implications for infection prevention precautions; 2021. Available from: https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions
Harmer D, Gilbert M, Borman R, et al. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin-converting enzyme. FEBS Lett 2002;532(1-2):107–110. DOI: 10.1016/s0014-5793(02)03640-2
World Health Organization. Coronavirus Disease (COVID-19) Outbreak. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (accessed on 7 September 2020)
Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020;2(8):1069–1076. DOI: 10.1007/s42399-020-00363-4
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report. Available online: www.goldcopd.org (accessed on 20 May 2020)
Pifarre R, Falguera M, Vicente-de-Vera C, et al. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007;101(10):2139–44. DOI: 10.1016/j.rmed.2007.05.011
Nicosia RF, Ligresti G, Caporarello N, et al. COVID-19 vasculopathy: mounting evidence for an indirect mechanism of endothelial injury. Am J Pathol 2021;191(8):1374–1384. DOI: 10.1016/j.ajpath.2021.05.007
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–1720. DOI: 10.1056/NEJMoa2002032
Pellicori P, McConnachie A, Carlin C, et al. Predicting mortality after hospitalization for COPD using electronic health records. Pharmacol Res 2022;179:106199. DOI: 10.1016/j.phrs.2022.106199
Andreassen SL, Liaaen ED, Stenfors N, et al. Impact of pneumonia on hospitalizations due to acute exacerbations of COPD. Clin Respir J 2014;8(1):93–9. DOI: 10.1111/crj.12043
Vestbo J, Waterer G, Leather D, et al. Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD. Eur Respir J 2022; 59(5):2102899. DOI: 10.1183/13993003.02899-2021
Linden D, Guo-Parke H, Coyle PV, et al. Respiratory viral infection: a potential “missing link” in the pathogenesis of COPD. Eur Respir Rev 2019;28(151):180063. DOI: 10.1183/16000617.0063-2018
Republic of Turkey Ministry of Health. Public Health Institution of Turkey Department of Combating Tobacco and Substance Addiction. Global Adult Tobacco Survey Turkey Report 2012:10–12.
Uğur Chousein EG, Çörtük M, Cınarka H, et al. Is there any effect of smoking status on severity and mortality of hospitalized patients with COVID-19 pneumonia? Tuberk Toraks 2020;68(4):371–378. DOI: 10.5578/tt.70352
Whittaker H, Rubino A, Müllerová H, et al. Frequency and severity of exacerbations of COPD associated with future risk of exacerbations and mortality: a UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis 2022;17:427–437. DOI: 10.2147/COPD.S346591
Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)–why and what? Clin Respir J 2012;6(4):208–214. DOI: 10.1111/crj.12002
Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J 2019;53(5):1900164. DOI: 10.1183/13993003.00164-2019
Mathioudakis AG, Janssens W, Sivapalan P, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax 2020;75(6):520–527. DOI: 10.1136/thoraxjnl-2019-214484
Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine 2021;33:100789. DOI: 10.1016/j.eclinm.2021.100789
Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020;55(5):2000688. DOI: 10.1183/13993003.00688-2020
Sinatti G, Santini SJ, Tarantino G, et al. PaO2/FiO2 ratio forecasts COVID-19 patients’ outcome regardless of age: a cross-sectional, monocentric study. Intern Emerg Med 2022;17(3):665–673. DOI: 10.1007/s11739-021-02840-7
Lang M, Som A, Mendoza DP, et al. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. Lancet Infect Dis 2020;20(12):1365–1366. DOI: 10.1016/S1473-3099(20)30367-4
Petersson J, Glenny RW. Gas exchange and ventilation-perfusion relationships in the lung. Eur Respir J 2014;44(4):1023–1041. DOI: 10.1183/09031936.00037014
Singh D, Long G, Cançado JED, et al. Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinician. Curr Opin Pulm Med 2020;26(2):162–168. DOI: 10.1097/MCP.0000000000000637
Jalde FC, Beckman MO, Svensson AM, et al. Widespread parenchymal abnormalities and pulmonary embolism on contrast-enhanced CT predict disease severity and mortality in hospitalized COVID-19 patients. Front Med (Lausanne) 2021;8:666723. DOI: 10.3389/fmed.2021.666723
Keresztesi AA, Perde F, Ghita-Nanu A, et al. Post-mortem diagnosis and autopsy findings in SARS-CoV-2 infection: forensic case series. Diagnostics (Basel) 2020;10(12):1070. DOI: 10.3390/diagnostics10121070
Santus P, Radovanovic D, Saderi L, et al. Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. BMJ Open 2020;10(10):e043651. DOI: 10.1136/bmjopen-2020-043651
Gu Y, Wang D, Chen C, et al. PaO2/FiO2 and IL-6 are risk factors of mortality for intensive care COVID-19 patients. Sci Rep 2011;11(1):7334. DOI: 10.1038/s41598-021-86676-3
Schuetz P, Maurer P, Punjabi V, et al. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013;17(3):R115. DOI: 10.1186/cc12787
Sohn KM, Lee SG, Kim HJ, et al. COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis. J Korean Med Sci 2020;35(38):e343. DOI: 10.3346/jkms.2020.35.e343
Kumar A, Karn E, Trivedi K, et al. Procalcitonin as a predictive marker in covid-19: a systematic review and meta-analysis. PLoS ONE 2022;17(9):e0272840. DOI: 10.1371/journal.pone.0272840
Gautam S, Cohen AJ, Stahl Y, et al. Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. Thorax 2020;75(11):974–981. DOI: 10.1136/thoraxjnl-2020-214896
Ergan B, Şahin AA, Topeli A. Serum procalcitonin as a biomarker for the prediction of bacterial exacerbation and mortality in severe COPD exacerbations requiring mechanical ventilation. Respiration 2016;91(4):316–324. DOI: 10.1159/000445440
Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020;55(5):2000524. DOI: 10.1183/13993003.00524-2020
Sartini S, Massobrio L, Cutuli O, et al. Role of SatO2, PaO2/FiO2 ratio and PaO2 to Predict Adverse Outcome in COVID-19: a Retrospective, Cohort Study. Int J Environ Res Public Health 2021;18(21):11534. DOI: 10.3390/ijerph182111534